PROCEPT BioRobotics (PRCT) Projected to Post Earnings on Thursday

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) is anticipated to release its earnings data before the market opens on Thursday, April 24th. Analysts expect PROCEPT BioRobotics to post earnings of ($0.49) per share for the quarter. Individual that wish to register for the company's earnings conference call can do so using this link.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01). The firm had revenue of $68.24 million for the quarter, compared to the consensus estimate of $66.79 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. On average, analysts expect PROCEPT BioRobotics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

PROCEPT BioRobotics Price Performance

NASDAQ PRCT traded up $0.22 on Friday, reaching $53.03. 868,416 shares of the stock traded hands, compared to its average volume of 782,183. PROCEPT BioRobotics has a 12 month low of $47.04 and a 12 month high of $103.81. The company has a market cap of $2.91 billion, a price-to-earnings ratio of -27.19 and a beta of 1.09. The firm's fifty day simple moving average is $59.16 and its 200 day simple moving average is $74.66. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21.

Wall Street Analysts Forecast Growth

PRCT has been the topic of a number of research analyst reports. Morgan Stanley lowered their target price on PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Truist Financial lowered their price objective on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating on the stock in a research note on Friday, April 11th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, PROCEPT BioRobotics has an average rating of "Moderate Buy" and a consensus price target of $91.43.

Insider Activity at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CFO Kevin Waters sold 733 shares of the firm's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $41,824.98. Following the completion of the sale, the chief financial officer now directly owns 107,991 shares in the company, valued at approximately $6,161,966.46. This trade represents a 0.67 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Reza Zadno sold 5,475 shares of the company's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $312,403.50. Following the completion of the transaction, the chief executive officer now owns 173,070 shares in the company, valued at $9,875,374.20. This represents a 3.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 6,455 shares of company stock worth $368,322 in the last quarter. 17.40% of the stock is owned by company insiders.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).